Argo Biopharma Secures IND Approval for Phase II Trial of BW-40202 in PNH

Argo Biopharma Secures IND Approval for Phase II Trial of BW-40202 in PNH

By, Admin 16 September 2025

Beijing, China — Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage siRNA therapeutics company, announced that China’s National Medical Products Administration (NMPA) has granted Investigational New Drug (IND) approval for a Phase II trial of BW-40202. The therapy targets complement factor B (CFB) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and other complement-mediated diseases.

The Phase II study is expected to begin in January 2026. BW-40202 is also being tested in a Phase I trial for IgA Nephropathy (IgAN) following a June 2025 IND clearance.

CEO Statement

“The IND approval for BW-40202 is an important milestone in our mission to redefine treatment for patients with PNH. This achievement underscores our innovative approach in targeting the complement system and moves us one step closer to delivering a potential new, targeted therapy to patients who need more treatment options.”

  • Dr. Dongxu Shu, co-founder and CEO of Argo Biopharma.

About BW-40202

  • Therapeutic class: siRNA drug targeting CFB mRNA in the liver.
  • Mechanism: Uses RNA interference (RNAi) to suppress CFB expression → reduces serum CFB protein levels → inhibits complement alternative pathway (CAP) activity.
  • Preclinical findings:
    - Strong purity and stability.
    - Durable suppression of serum CFB protein.
    - Effective CAP inhibition.
    - Favorable safety and pharmacological profile.

Understanding PNH

  • Prevalence: Affects 10–20 people per million globally.
  • Key symptoms: Severe anemia, hemoglobinuria, blood clots, kidney disease, pulmonary hypertension.
  • Risks: Thrombosis is the most life-threatening complication, linked to 40–67% of PNH-related deaths.
  • Why siRNA matters: Offers precise targeting, long-lasting efficacy, fewer doses, and improved safety, potentially raising treatment standards in complement-driven diseases.

About Argo Biopharma

  • Clinical-stage biotech focused on next-generation RNAi therapies.
  • Pipeline covers cardiovascular, viral, metabolic, and rare diseases.
  • Currently advancing six RNAi candidates in clinical development.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!